Solutions for SARS-CoV-2 Detection
We are here to help laboratories overcome their SARS-CoV-2 testing challenges so they can better address the world’s urgent public health concerns. We are working closely with laboratories around the world to deliver the nucleic acid isolation, automation, real-time PCR, antibody testing, and vaccine development solutions they need to rapidly respond to these challenges. Our top priority is to provide the technology and support to meet these needs.
Explore our SARS-CoV-2 Testing Products
PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel 1 – EUA
The FDA EUA authorized PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel 1 is a real-time RT-PCR multiplexed test intended for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A, influenza B, and RSV.
PerkinElmer® COVID-19 Antigen Test
Enable your POC testing with the PerkinElmer® COVID-19 Antigen Test, a simple, rapid, and reliable lateral flow immunoassay test used to screen or diagnose asymptomatic or symptomatic individuals for COVID-19.
Simultaneous COVID-19, Flu, and RSV Test
Detect and differentiate SARS-CoV-2, influenza A, influenza B, and RSV in a single sample with the CE-IVD marked PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel. This workflow enables labs to conserve resources while testing a single sample for multiple pathogens.
COVID-19 Testing Lab-In-A-Lab Service
Increase your SARS-CoV-2 testing capabilities with the COVID-19 Lab-In-A-Lab™ testing solution, a full-service turnkey testing option embedded in your CLIA certified lab.
PerkinElmer® GSP®/DELFIA® Anti-SARS-CoV-2 IgG Kit CE-IVD
The PerkinElmer® GSP®/DELFIA® Anti-SARS-CoV-2 IgG kit delivers qualitative detection of human IgG antibodies against SARS-CoV-2 in dried blood spots (DBS), plasma, and serum to identify individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.
Automated, high-throughput processing of DBS is available with the GSP® instrument.
Manual processing of plasma and serum samples is available with the VICTOR2™ D instrument.
SARS-CoV-2 Test systems from EUROIMMUN a PerkinElmer Company
The complete package for SARS-CoV-2 virus and antibody detection.
Remote Services
Resolve instrument repairs faster and increase uptime. OneSource remote options do just that. Remote Support and Radian™ Remote Diagnostic services.
Maximize Your SARS-COV-2 Testing Efficiency
PerkinElmer offers complete workflow solutions including reagents, instrumentation, and consumables for the detection of SARS-CoV-2 RNA and the screening for SARS-CoV-2 antibodies. With the ability to process up to 10,000 samples/day, the scalable and modular explorer™ automated workstations along with a reliable supply of PerkinElmer’s reagents and consumables can maximize the efficiency of your SARS-CoV-2 testing 24/7.
Webinar
News Stories
The Future of COVID Testing
Prahlad Singh, President and CEO of PerkinElmer, sat down with This Week in Business on NECN to talk about the Company’s COVID-19 RT-PCR and antigen tests, and how he perceives the COVID-19 testing landscape to be as vaccines roll out.
Read MoreBlog Posts
Coronalab.eu Travel Clinic
Read our blog post to learn about CoronaLab, a business unit of Microbe&Lab B.V., which provides cutting-edge SARS-CoV-2 RT-PCR testing for non-symptomatic people.
Read MoreNavigating the FDA’s EUA Process for Diagnostics
Dr. Elizabeth Hillebrenner, associate director for scientific and regulatory programs at the FDA’s Center for Devices and Radiological Health, kicked off this virtual roundtable with an overview of the EUA program, how it evolved, and how lessons learned during the current pandemic may shape future policies and actions by the FDA. She then took part in a panel discussion that included a variety of stakeholders from the diagnostics and clinical lab industries.
Read MoreAnterior Nasal Swabs for COVID-19 Testing
The FDA has authorized a new sample type, anterior nasal swabs, for use with some EUA authorized real-time RT-PCE assays for COVID-19 testing. Using anterior nasal swabs for SARS-CoV-2 testing offers many advantages over the typical sample types, human oropharyngeal and nasopharyngeal swab samples.
Read MoreImportance of Immunoassays for Coronavirus Control
On December 31, 2019, a pneumonia case in the Chinese city, Wuhan, with unknown pathological origin, was reported into the Chinese World Health Organization (WHO) office. By March 11, 2020, the virus had spread to 114 countries and had taken nearly 4,300 lives leading WHO to declare COVID-19 a global pandemic (WHO, 2020).
Read MoreHow to Handle Inconclusive Samples with SARS-CoV-2 Real-Time PCR Tests
SARS-CoV-2 real-time reverse transcription polymerase chain reaction (RT-PCR) tests, can be inaccurate in two ways, as can all diagnostic assays. A false-positive result mistakenly identifies a person as infected, resulting in unnecessary quarantine and contact tracing. False-negative results are far more problematic because infected people may not isolate themselves and can infect others.
Choosing a SARS-CoV-2 Real-Time RT-PCR Assay
Accurate detection of SARS-CoV-2 is critical for both patient treatments, as well as control of the COVID-19 pandemic. Many factors need to be considered when choosing a workflow to use for SARS-CoV-2 detection.
Read MoreEnsuring the Accuracy of your SARS-CoV-2 Testing Results
Accuracy of SARS-CoV-2 testing is critical when determining if someone is infected and needs to be quarantined and/or treated for a coronavirus infection. Real-time reverse transcription polymerase chain reaction (RT-PCR) assays are the tool of choice for determining if someone has an active viral shedding of SARS-CoV-2. RT-PCR assays reverse transcribe the viral RNA into DNA for amplification and subsequent identification of target regions.
Read MoreSignificance & Difference between Target Regions for SARS-CoV-2 Testing
Severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2, the virus responsible for the disease known as COVID-19, is now a global pandemic. This novel coronavirus was first observed in humans in December of 2019 and sequenced by multiple teams over the next month (Wu et al., 2020; Zhu et al., 2020; Chan et al., 2020).
Read More